Original Research ARTICLE
Plasma Protein Pattern Correlates With Pain Intensity and Psychological Distress in Women With Chronic Widespread Pain
- Pain and Rehabilitation Centre, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
Objectives: Although generalized muscle pain, tiredness, anxiety, and depression are commonly present among chronic widespread pain (CWP) patients, the molecular mechanisms behind CWP are not fully elucidated. Moreover, the lack of biomarkers often makes diagnosis and treatment problematic. In this study, we investigated the correlation between pain intensity, psychological distress, and plasma proteins among CWP patients and controls (CON).
Methods: The plasma proteome of CWP (n = 15) and CON (n = 23) was analyzed using two-dimensional gel electrophoresis. Orthogonal Partial Least Square analysis (OPLS) was used to determine proteins associated with pain intensity (numeric rating scale) in CWP and psychological distress (Hospital and Depression Scale, HADS) in CWP and CON. Significant proteins were identified by MALDI-TOF and tandem MS.
Results: In CWP, pain intensity was associated with plasma proteins mostly involved in metabolic and immunity processes (e.g., kininogen-1, fibrinogen gamma chain, and ceruloplasmin), and psychological distress was associated with plasma proteins related to immunity response, iron ion, and lipid metabolism (e.g., complement factor B, complement C1r subcomponent, hemopexin, and clusterin).
Discussion: This study suggests that different plasma protein patterns are associated with different pain intensity and psychological distress in CWP. Proteins belonging to the coagulation cascade and immunity processes showed strong associations to each clinical outcome. Using the plasma proteome profile of CWP to study potential biomarker candidates provides a snapshot of ongoing systemic mechanisms in CWP.
Chronic widespread pain (CWP), including fibromyalgia syndrome (FMS), is a complex pain condition characterized by generalized musculoskeletal pain and is often associated with symptoms such as tiredness, sleep disturbance, depression, anxiety, and cognitive difficulties (Wolfe et al., 1990; Aparicio et al., 2013; Perez de Heredia-Torres et al., 2016). Chronic pain not only affects the patients but also affects their families and society, leading to extensive suffering and high economic costs (Breivik et al., 2006).
Diagnosis of CWP is based on clinical examinations and criteria included in the American College of Rheumatology (ACR 90) definition of FMS (Wolfe et al., 1990). Hence, CWP means that pain has to be chronic (>3 months duration) and widespread (i.e., in the spine and in at least three out of four defined body quadrants or in the spine and in contralateral quadrants). Diagnosis of FMS also requires generalized hyperalgesia (examined using tender point examination). In the European adult population, the prevalence of CWP is about 10%, with a higher prevalence for females (Bergman et al., 2001; Breivik et al., 2006; Cimmino et al., 2011; Mansfield et al., 2016). Furthermore, the variety of symptoms among CWP and the complex multifactorial etiology make it difficult to study the biological mechanisms behind CWP, mechanisms that need further elucidation. Although both central and peripheral mechanisms may contribute to the perceived pain in CWP, (Staud et al., 2001, 2009; Flodin et al., 2014) no valid biological markers have been identified for the activated nociceptive mechanisms in chronic pain conditions, including CWP. This and other studies from our group focus on exploring such activated mechanisms with the long-term goal of identifying clinically applicable biomarkers that can facilitate mechanism-based diagnoses and choice of treatments. Many biomarker studies have analyzed protein patterns, cytokines/chemokines, lipids, and metabolites in plasma/serum, muscles, and saliva to understand activated nociceptive mechanisms in patients with CWP/FMS (Bazzichi et al., 2009; Zanette et al., 2014; Hadrevi et al., 2015; Culic et al., 2016; Gerdle et al., 2017; Olausson et al., 2017; Wåhlén et al., 2017). Taken together, these studies clearly indicate that peripheral (muscle and/or blood) nociceptive and inflammatory mechanisms are active and differ between patients and healthy controls.
One important aspect of pain both clinically and in research is pain intensity, which is registered using self-reported pain scales such as numeric rating scale (NRS) or visual analog scale (VAS) (Farrar et al., 2001; Ferreira-Valente et al., 2011; Kliger et al., 2015). Recently, we reported that pain intensity correlated significantly with the muscle protein pattern in CWP (Olausson et al., 2016) and that several of the identified significant proteins were involved in stress and inflammatory responses and metabolic pathways. However, it is not known whether such a relationship exists between pain intensity and the protein pattern in blood. As mentioned above, psychological distress is common in CWP and is often measured using the Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983). Because the association between depression and several serum proteins has been shown in patients with major depression disorder, (Lee et al., 2015; Ruland et al., 2016) it is important to investigate whether the protein pattern in blood correlates with psychological distress in CWP patients and to what extent these proteins influence pain intensity. The same principal reasoning goes for Body Mass Index (BMI) since increased BMI is often found in patients with CWP/FMS (Neumann et al., 2008) and the correlation between limited numbers of plasma/serum metabolites and proteins and BMI have been reported (Xiao et al., 2013; Rus et al., 2016).
Using proteomics to investigate disease specific markers in plasma and serum is common in the cardiovascular, cancer, and neurodegenerative research (Geyer et al., 2017). There are at least two advantages with analyzing plasma: its rich protein content is easily accessed and since blood is in direct contact with all tissues, changes in peripheral tissues can be easily detected (Anderson and Anderson, 2002). However, plasma proteomic studies comprise several challenges. Plasma contains a complex mixture of proteins with large dynamic range, dominated by high abundant proteins such as albumin and immunoglobulins (Anderson and Anderson, 2002). Multidimensional fractionation or depletion techniques are required to sufficiently reduce sample complexity (Cao et al., 2012). Mass spectrometry in combination with various separation methods such as two-dimensional gel electrophoresis (2-DE) and liquid chromatography (LC) can identify thousands of proteins in a single analysis, and this information can be used to study how proteins are expressed and regulated (Gorg et al., 2009; Westermeier and Gorg, 2011). This strategy has successfully been applied in multiple quantitative proteomic studies of the cerebral spinal fluid (CSF) and serum of subjects with chronic low back pain (with and without pain related to lumbar disk hernia) (Liu et al., 2006; Zhang et al., 2014). Compared to other separation methods, 2-DE provides a high quality of protein resolution as shown by its capability to resolve many post-translationally modified proteins that appear as isoforms.
Previously, we used 2-DE to investigate the plasma proteome between CWP patients and healthy controls (Wåhlén et al., 2017). We found several proteins belonging to inflammatory, immunity, and metabolic processes that could discriminate the CWP and CON group. Based on these results, we now want to investigate the correlation between the altered proteins and pain intensity, depression, and anxiety. To the best of our knowledge, this type of investigation has not been reported. The analysis of the plasma proteome and investigation of associated symptoms in CWP patients using proteomics could improve the knowledge of the activated biological mechanisms in CWP.
Here, we investigated the correlation between pain intensity, psychological distress, and plasma proteins among CWP patients and controls and analyzed the possible influences of BMI and age on such relationships.
Materials and Methods
The recruitment process, including inclusion and exclusion criteria, for CWP patients and healthy controls (CON) has previously been described in detail (Gerdle et al., 2014). None of the included subjects used any type of opioid, steroidal, or anticoagulatory medication. Exclusion criteria also included medical history record of bursitis, tendonitis, capsulitis, post-operative conditions in the neck/shoulder area, previous neck trauma, disorder of the spine, neurological disease, rheumatoid arthritis or any other systemic diseases, metabolic disease, malignancy, severe psychiatric illness or pregnancy, or difficulties understanding the Swedish language.
The healthy CON group consisted of women between 20 and 65 years. They were recruited through local newspaper advertisements. Women with CWP were recruited from former patients with CWP at the Pain and Rehabilitation Centre of the University Hospital, Linköping, Sweden and from an organization for FMS patients. As reported in previous studies, (Gerdle et al., 2010, 2014; Ghafouri et al., 2013) a total of 19 CWP and 24 CON were initially recruited in the original study. However, four participants were not used because there were difficulties collecting blood samples (two CWP subjects) and because two plasma samples (one CWP and one CON) were insufficient for further proteomic analysis. This resulted in 16 CWP and 23 CON samples. Hence, the proteomic data that this present study is based on has previously been published (Wåhlén et al., 2017). However, in this present study, one of the CWP patients was excluded due to unclear diagnosis after detailed analysis and due to the fact that this patient had incomplete data in the health questionnaire. This exclusion resulted in statistical analysis of 38 plasma samples in this present study, 15 plasma samples from CWP and 23 from CON.
To confirm the individual eligibility, all participants (CWP and CON) received a standardized clinical examination. The ACR 90 criteria were used for classification of FMS/CWP (Wolfe et al., 1990). The recruiting process started in January 2010 and finished in May 2011. Hence, the revised ACR criteria from 2016 was not available. The examination was followed by a health questionnaire (see below). At the clinical examination, weight and height were registered. Based on these measurements, BMI (kg/m2) was calculated as weight (kg)/height (m)2 and classified according to the criteria developed by the World Health Organization (WHO): < 18.5 = underweight; 18.5–24.9 = normal range; 25.0–29.9 = overweight; and ≥30.0 = obesity.
All participants signed a written consent form before the start of the study after receiving verbal and written information about the objectives and procedures of the study. The study was approved by the Regional Ethical Review Board in Linköping, Sweden (Dnr: M10–08, M233–09, Dnr: 2010/164–32) and followed the guidelines according to the Declaration of Helsinki. All methods were carried out in accordance with the approved ethical application.
All subjects answered a health questionnaire consisting of the following items and scales.
Each subject reported age (years).
Pain Intensity and Duration
Each subject rated the pain intensity in the neck-shoulder region, low back and whole body using an 11 grade (0 – 10) NRS with two endpoints: zero indicating no pain at all and 10 indicating worst possible pain (Ferreira-Valente et al., 2011). CWP patients also reported the pain duration (years).
Hospital Anxiety and Depression Scale (HADS)
The HADS is a short self-assessment questionnaire that measures anxiety and depression (Zigmond and Snaith, 1983). HADS comprises seven items in each of the depression and anxiety scales (HAD-Depression and HAD-Anxiety). The subscale scores range between 0 and 21, with the lower score indicating the least depression and anxiety possible (Zigmond and Snaith, 1983). HADS is frequently used both in clinical practice and in research and has good psychometric characteristics (Zigmond and Snaith, 1983; Bjelland et al., 2002). It is also validated in its Swedish translation (Lisspers et al., 1997). In this study, a total score of HADS (denoted HADS-total), which includes both the anxiety and depression scores, was used to indicate psychological distress.
Other Background Variables
To get a comprehensive description of the subjects also data from the Pain Catastrophizing Scale (PCS) and Quality of Life instrument (QoL) are reported; for details about these instruments see our previous studies (Gerdle et al., 2014; Wåhlén et al., 2017).
Before blood sampling, all participants were asked not to take any non-steroidal anti-inflammatory drugs for 7 days and/or paracetamol medication 12 h before the sampling. Venous blood samples were collected in EDTA vacutainer and centrifuged at 1000 × g for 15 min. The plasma was collected, aliquoted, and stored at −70°C. All samples were blinded before analysis.
Two-Dimensional Gel Electrophoresis (2-DE)
The procedure for 2-DE, including sample preparation, has previously been described in detail (Gorg et al., 2009; Olausson et al., 2015; Wåhlén et al., 2017). In brief, depleted plasma samples containing 100 μg total protein were run in the first dimension, followed by second dimension separation using EttanTM DALTsix Electrophoresis Unit (Amersham, Pharmacia, Uppsala, Sweden). The protein gels were fluorescently stained using SYPRO Ruby® (Bio-Rad Laboratories, Hercules, CA, United States). The stained protein pattern was visualized using a charge coupled device camera (VersaDocTM Imaging system 4000 MP, Bio-Rad) and further analyzed and quantified using PDQuest Advanced (v. 8.0.1, Bio-Rad). The amount of protein in a spot was assessed as background-corrected optical density, integrated over all pixels in the spot, and expressed as integrated optical density (IOD). Quantified protein data were then analyzed with multivariate statistics. The coefficient of variation of 2-DE was less than 25%, which is in line with what others have found with 2-DE (Magdeldin et al., 2014). Two preparative gels (one pool from CWP and one from CON, containing 400 μg of total protein) for protein identifications were run according to the above protocol.
For identification, protein spots of interest were excised from the preparative gels, de-stained, subjected to tryptic digestion, and prepared as previously described (Olausson et al., 2015). Briefly, the gel piece was incubated in 50% acetonitrile (ACN) in 25 mM ammonium bicarbonate, dehydrated in 100% ACN, dried in SpeedVac, and trypsinated in 37°C over night. The supernatant was transferred to a new tube, and the peptides were further extracted from the gel piece by incubation of 5% trifluoroacetic acid (TFA) in 50% ACN for 4 h. The pooled supernatants were dried and stored at −20°C until analysis.
Briefly, for MALDI-TOF analysis, peptides were reconstituted in 4 μl 0.1% TFA. The peptides were mixed in a 1:1 ratio with matrix solution (dihydroxybenzoic acid in 70% acetonitrile/0.3% TFA) and 1 μl was spotted on a target plate (stainless steel). The peptide masses were analyzed and the mass range of 300–3500 Da was used, including external mass calibration using a peptide calibration standard (Bruker) (Olausson et al., 2017).
Low abundant proteins were identified with a nano liquid chromatography system (EASY-nLC, Thermo Scientific, Waltham, MA, United States) coupled to an LTQ Orbitrap Velos Pro MS (Thermo Scientific). The same procedure for LC-MS analysis was used as described earlier with minor adjustments in time (Olausson et al., 2017). Peptides were dissolved in 6 μl 0.1% formic acid (FA) and loaded on a C18 column (100 mm × 75 μM, particle size 5 μM). The flow rate was set to 300 nL/min and the gradient buffer contained 0.1% FA in water (buffer A) and 0.1% FA in ACN (buffer B). Buffer B was used in a linear gradient (0–100%) for 30 min to separate the peptides.
Database Search and Bioinformatics
The acquired MS data from MALDI-TOF analysis was pre-processed using flexAnalysis v. 3.4 (Bruker Daltonik), and the major peak list from each processed spectra was imported in the search engine ProteinProspector MS-Fit (v. 5.14.4), including the Swiss-Prot database v. 2015.3.5, as described in previous studies (Olausson et al., 2017; Wåhlén et al., 2017). Parameter restriction was made based on species (Homo sapiens), mass tolerance (50 ppm), maximum miss cleavages by trypsin (≤1), fixed modifications (carbamidomethylation of cysteine), and possible dynamic modifications (oxidation of methionine).
The acquired MS data from the Orbitrap were analyzed with MaxQuant v. 18.104.22.168 (Max Planck Institute of Biochemistry, Martinsried, Germany) using the human UniProt/Swiss-Prot database (downloaded 20170404) as described previously (Olausson et al., 2017). The analysis parameters were as follow: mass tolerance (0.5 Da), parent ion tolerance (6 ppm), miss cleavages by trypsin (maximum 2), fixed modifications (carbamidomethylation of cysteine), and variable modification (oxidation on methionine and N-terminal acetylation). A false discovery rate of <1% was used and at least two unique peptides were needed to be considered as identified. The identified proteins were divided in different groups based on UniProt database1 definition on biological process.
For comparison of group differences regarding clinical background data, pain intensity, and HADS, Student’s t-test and the non-parametric Mann–Whitney U-test were applied (IBM SPSS v. 24.0, IBM, United States) for normal distributed data and for non-normally distributed data, respectively, p < 0.05 was considered significant.
Multivariate Data Analysis (MVDA)
To investigate the multivariate correlations between the proteins (X-variables) and the clinical variables (Y-variables), OPLS was applied using SIMCA-P+ v. 13.0 (UMETRICS, Umeå, Sweden) (Eriksson et al., 2006). When applying MVDA, we followed the recommendations concerning omics data presented by Wheelock and Wheelock (Wheelock and Wheelock, 2013). The procedure of MVDA has been described in detail elsewhere (Olausson et al., 2015, 2017; Wåhlén et al., 2017).
Briefly, PCA was used before all OPLS analysis in order to check for multivariate outliers. Furthermore, OPLS was used for the regression analyses of pain intensity, depressive and anxiety symptoms (HADS-total), BMI, and age using the detected proteins as regressors (X-variables) and clinical variables as Y-variables. All variables were mean centered, scaled for unified variance (UV-scaling), and transformed (log) if necessary (Eriksson et al., 2006). Variable influence on projection (VIP) value >1.0 combined with jack-knifed 95% confidence intervals in the regression coefficients plot not including zero were considered significant. In the present study, the analysis was made in two steps. First, all proteins were included and from this analysis selected proteins with VIP > 1.0 were used in a new regression presented in the results. Second, the significant (VIP > 1.0) proteins were identified. In the tables, p(corr) is presented for each significant variable. This is the loading of each variable scaled as a correlation coefficient and thus standardizing the range from −1 to +1 (Wheelock and Wheelock, 2013). Furthermore, for each OPLS model, R2 and Q2 are displayed describing the goodness of fit and goodness of prediction of each model (Eriksson et al., 2006). To validate the model, we used cross validated analysis of variance (CV-ANOVA), and p ≤ 0.05 was considered a significant model. All presented variables are in accordance with Wheelock and Wheelock (Wheelock and Wheelock, 2013).
Clinical Background Data
No significant differences were found between CWP and CON regarding height, weight, and BMI. The CWP group was significantly older and reported significantly higher HADS-total compared to CON. As expected, the pain intensity, as measured by NRS, was significantly higher in the CWP group. CWP also reported lower quality of life as well as more catastrophizing thoughts (Table 1).
TABLE 1. Demographic data, clinical measurements of pain intensity (NRS) and other pain characteristics, presented as mean values (±1 standard deviation) and median (min–max).
A total of 414 ± 21 (CWP: 425 ± 18, CON: 408 ± 20) plasma proteins, including different isoforms (in the following termed proteoforms) from each gel, were detected in the 2-DE analysis, and 325 proteins were further quantified, matched, and analyzed with OPLS models. The quantified proteins were initially analyzed with an unsupervised PCA to detect outliers. In this study, no moderate or strong outliers were found. Most of the significantly protein spots were identified in previous study (Wåhlén et al., 2017). There were 57 proteins that were not identified previously and these spots were excised from the gel and identified by mass spectrometry (Supplementary Table S1 and Supplementary Figure S1).
In total, seven OPLS models were created to analyze the correlation between expressed plasma proteins and NRS, HADS-total, BMI, and age in CWP and CON. The following protein distributions in all models were found – metabolic: CWP = 41% and CON = 35%; immunity: CWP = 30% and CON = 37%; iron ion homeostasis: CWP = 8% and CON = 8%; inflammatory: CWP = 4% and CON = 15%; lipid metabolism: CWP = 18% and CON = 3%; and unknown processes: CWP = 0% and CON = 2%.
Plasma Proteins in Relation to Pain Intensity (NRS) in the CWP Group
The OPLS model of NRS (NRSCWP) consisted of one predictive and one orthogonal component with a high sensitivity (R2 = 0.97), predictivity (Q2 = 0.85), and a significant CV-ANOVA (p-value < 0.001). A total of 20 proteins had a VIP value >1.0 and were considered significant regressors for NRS (Y-variable) in the CWP (Figure 1A). In the score plot of NRSCWP (Figure 1B), a separation within the group is seen based on the respective NRS value, representing mild (0–3), moderate (4–6), and severe (7–10) pain intensity. The majority of the significant proteins belonged to metabolic and immunity processes, and other proteins belonged to lipid metabolism, iron ion homeostasis, and inflammatory processes (Table 2).
FIGURE 1. Orthogonal partial least squares regression analysis model of NRS in CWP. (A) Loading plot showing proteins with VIP value >1.0 significantly associated to pain intensity, e.g., fibrinogen gamma chain, ceruloplasmin, and plasminogen. The proteins are grouped based on biological process. (B) Score plot illustrating separation within the CWP group based on reported pain intensity: mild (0–3), moderate (4–6), and severe (7–10). NRS, numeric rating scale; CWP, chronic widespread pain; OPLS, orthogonal partial least squares regression analysis.
TABLE 2. Orthogonal partial least squares regression analysis model of pain intensity (NRS) in CWP group.
The five proteins with the highest VIP values (VIP > 1.18) and strongest associations with NRS were ceruloplasmin (iron ion homeostasis process), alpha-1B-glycoprotein, kininogen-1, and two proteoforms of fibrinogen gamma chain (metabolic processes) (Table 2). These proteoforms are shown on a 2-DE gel (marked in black) to visualize the plasma protein pattern and the quantified intensity from individual samples in each group (Figure 2). The spot numbers on the gel correspond to the spot numbers in Table 2.
FIGURE 2. Plasma protein pattern and significant proteoforms from the OPLS models of NRS and HADS-total CWP. The preparative 2-DE gel (used for protein identification) was used to visualize the plasma proteome. Marked proteoforms represent the five most important proteins with highest VIP value for the OPLS model in NRS (marked in black) and HADS-total in CWP (marked in red). The quantified intensity (Y-axis) of the proteoform in individual samples (X-axis) in CWP and CON group is illustrated in the diagrams. The numbers refer to equal numbers in each table of the respective model. NRS, numeric rating scale; CWP, chronic widespread pain; CON, control; HADS, hospital anxiety and depression scale; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis; PPM, part per million.
Plasma Proteins Versus HADS-Total
The OPLS model for HADS (HADSCWP) consisted of one predictive and one orthogonal component with a high sensitivity (R2 = 0.96), predictivity (Q2 = 0.70), and a significant CV-ANOVA (p-value = 0.011).
A total of 18 proteins had a VIP value >1.0 and were considered significant regressors for HADS-total (Y-variable) in the CWP group (Figure 3A). In the score plot of HADSCWP, a within group separation is seen among CWP based on the reported HADS-total score (Figure 3B), representing normal (0–14), mild (15–20), and moderate (21–28) psychological distress.
FIGURE 3. Orthogonal partial least squares regression analysis model HADS-total in the CWP. (A) Loading plot corresponding to proteins with a VIP value >1.0 associated to psychological distress are illustrated. The proteins with strongest association to psychological distress are the immunity proteins complement factor B and complement C1r subcomponent and the iron ion homeostasis protein hemopexin. (B) Score plot showing a within group separation among CWP based on reported HADS-total score. The plot shows that CWP patients are grouped as normal (0–14), mild (15–20), and moderate (21–28) psychological distress. CWP, chronic widespread pain; HADS, hospital anxiety and depression scale; VIP, variable influence on projection; OPLS, orthogonal partial least squares regression analysis.
Among the important proteins, the majority of the proteins belonged to immunity processes. Other proteins belonged to inflammatory processes, iron ion homeostasis, lipid metabolism, and metabolic processes (Table 3).
The five proteins with highest VIP value (VIP > 1.23) were one upregulated proteoform of complement C1r subcomponent (immunity process), complement factor B (immunity process), and hemopexin (iron ion homeostasis process) and two down regulated proteoforms of clusterin (lipid metabolism process) (Table 3). These proteoforms are shown on the 2-DE gel (marked in red) with quantified intensity from individual samples in each group (Figure 2). The spot numbers correspond to spot numbers in Table 3.
The OPLS model for CON of HADS-total (HADSCON) had one predictive component and one orthogonal component with good sensitivity (R2 = 0.84), moderate predictivity (Q2 = 0.48), and a significant CV-ANOVA (p-value = 0.016). A total of 12 proteins had a VIP value >1.0 and were considered significant important regressors for HADS (Y-variable) in the CON group. The identified proteins belonged to metabolic, immunity, inflammatory and unknown function, where majority of the proteins were metabolic proteins. For more details, see Supplementary Figure S2 and Supplementary Table S2.
OPLS Models of BMI in CON and CWP
To evaluate the correlation of BMI and expressed plasma proteins, an OPLS model of BMI in the CON group (BMICON) was analyzed. The OPLS model for BMICON consisted of one predictive and one orthogonal component with good sensitivity (R2 = 0.85), lower predictivity (Q2 = 0.42), and a significant CV-ANOVA (p-value = 0.038).
A total of 31 proteins had a VIP value >1.0 and were considered significant important regressors for BMI (Y-variable) in the CON group (Figure 4). The majority of the proteins belonged to immunity and metabolic processes.
FIGURE 4. Orthogonal partial least squares regression analysis model BMI in CON. Loading plot illustrating proteins with a VIP value >1.0 associated with BMI. The majority of the proteins belonged to immunity and metabolic responses. Several inflammatory proteins were also present. OPLS, orthogonal partial least squares regression analysis; VIP, variable influence on projection; CON, control; BMI, body mass index.
The proteins with highest VIP values (VIP > 1.40) were two upregulated proteoforms of haptoglobin (inflammatory process) and one proteoform each of alpha-1-antitrypsin, plasminogen, and serum amyloid P-component (metabolic processes) (Table 4).
The OPLS model of BMI for CWP (BMICWP) consisted of one predictive and one orthogonal component with high sensitivity (R2 = 0.92), predictivity (Q2 = 0.70), and significant CV-ANOVA (p-value = 0.011). A total of 21 proteins had a VIP value >1.0 and were considered significant important regressors for BMI (Y-variable) in the CWP group. The identified proteins belonged to immunity, lipid metabolism, and metabolic processes. For more details, see Supplementary Figure S3 and Supplementary Table S3.
OPLS Models of Age in CON and CWP
To evaluate the influence of age on the expressed plasma proteins, an OPLS model of age in CON (AgeCON) was analyzed. The OPLS model AgeCON had one predictive and one orthogonal component and showed high sensitivity (R2 = 0.89), predictivity (Q2 = 0.76), and a significant CV-ANOVA (p-value < 0.001). A total of 19 proteins had a VIP value >1.0 and were considered significant important regressors for age (Y-variable) in the CON group (Figure 5). Proteins belonging to immunity, inflammatory, iron ion homeostasis, lipid metabolism, and metabolic processes were present.
FIGURE 5. Orthogonal partial least squares regression analysis model of age in CON. Loading plot illustrating proteins with a VIP value >1.0. A variety of different protein groups were present, and proteins with highest VIP value and strongest association to age were one proteoform of haptoglobin and antithrombin-III. OPLS, orthogonal partial least squares regression analysis; VIP, variable influence on projection; CON, control; BMI, body mass index.
The five proteins with highest VIP values (VIP > 1.28) were two upregulated proteoforms of fibrinogen alpha chain (metabolic process) and one proteoform of haptoglobin (inflammatory process). One proteoform of Ig alpha-2 chain C region (immunity process) and antithrombin-III (metabolic process) was downregulated (Table 5).
The OPLS model of Age in CWP (AgeCWP) had one predictive and one orthogonal component and showed high sensitivity (R2 = 0.94), predictivity (Q2 = 0.77), and a significant CV-ANOVA (p-value = 0.003). A total of 12 proteins had a VIP value >1.0 and were considered significant important regressors for age (Y-variable) in the CWP group. Proteins belonging to immunity, iron ion homeostasis, lipid metabolism, and metabolic processes were present. For more details, see Supplementary Figure S4 and Supplementary Table S4.
Shared Proteoforms – Compensating for Possible Cofounding Effects of Age and BMI
To avoid possibly confounding effects of age and BMI on NRS and HADS-total, we compared the models of age and BMI in CON with the models of NRS and HADS-total in CWP. Shared proteoforms were eliminated from the models of NRSCWP and HADSCWP, and the models were recalculated.
In the OPLS models of BMICON and AgeCON, four proteoforms with a VIP >1.0 (spot number 2116, 2903, 4316, and 4809) were also present in the NRSCWP model. These proteoforms were excluded from the obtained NRSCWP model and the model was re-calculated. The new also significant OPLS model of NRSCWP only had slightly changed parameters (R2 = 0.96, Q2 = 0.84, CV-ANOVA; p < 0.001) and 16 proteins with a VIP > 1.0 (the same proteins as in first model).
One proteoform (spot number 7120) was shared between the OPLS model of AgeCON and HADSCWP. No proteoforms were shared between BMICON and HADSCWP. To investigate whether age had a possible cofounding effect on HADS in the models, the shared proteoform was excluded from HADSCWP and a new model was calculated. The new resulting OPLS model for HADSCWP was very similar to the first (R2 = 0.96, Q2 = 0.66, CV-ANOVA; p < 0.05), with a slightly lower R2-value and with the same proteins as important regressors with a VIP > 1.0.
Compensating for Possible Cofounding Effects of HADS-Total Upon NRSCWP
After comparing the OPLS models of NRSCWP and HADSCWP, one proteoform (spot number 114) was shared and therefore excluded in both models. The new model of NRSCWP (R2 = 0.96, Q2 = 0.84, CV-ANOVA; p < 0.001) and HADSCWP (R2 = 0.96, Q2 = 0.66, CV-ANOVA; p < 0.05) had unchanged parameters compared to previous ones.
Other Shared Proteoforms
In total, 16 proteoforms were shared among other OPLS models. One proteoform of alpha-1-antitrypsin (spot number 2904) was shared between OPLS model NRSCWP and AgeCWP, and one proteoform of alpha-1-antitrypsin (spot number 2202) was shared between models BMICON and AgeCON. Furthermore, two proteoforms of clusterin were shared among AgeCWP and BMICON (spot number 131) and HADSCWP and AgeCWP (spot number 1113). Two proteoforms of complement C4-B (spot number 7216 and 8101) was shared between HADSCON and BMICON. Fibrinogen alpha chain (spot number 8719) was shared between AgeCON and BMICWP. Fibrinogen gamma chain (spot number 4302 and 4304) was present in both NRSCWP and BMICWP. One proteoform N-acetylmuramoyl-L-alanine amidase (spot number 5721) was present in AgeCWP and BMICWP. Three proteoforms of plasminogen were present in several OPLS models: HADSCWP and HADSCON (spot number 7819) and NRSCWP and HADSCON (spot number 8822 and 8909). Two proteoforms of secretory immunoglobulin chain alpha (spot number 4713 and 4807) was present in NRSCWP and BMICWP. Finally, one proteoform of complement factor I light chain (spot number 1111) was present in AgeCWP and BMICON models.
The following are the major results in this present exploratory proteomic study of the plasma in CWP:
• Pain intensity in CWP was associated with several plasma proteins involved in metabolic and immunity processes such as kininogen-1, fibrinogen gamma chain, and ceruloplasmin.
• Psychological distress in CWP was associated with plasma proteins related to immunity response and iron ion metabolism such as complement factor B, complement C1r subcomponent, and hemopexin.
• Proteomics in combination with multivariate statistics can be used to analyze associations between plasma proteins and pain intensity, psychological distress, BMI, and age in CWP and CON.
Overall, investigating the plasma proteome and proteins associated with different clinical measurements, as exemplified in this study, reveals different protein patterns for pain intensity and psychological distress. MVDA is commonly used in proteomic studies to analyze complex biofluids such as urine, plasma, serum, and CSF from CWP (Hadrevi et al., 2015; Backryd et al., 2017a,b; Malatji et al., 2017; Wåhlén et al., 2017). By including the analysis of BMI and age, possible cofounding effects on proteins in each specific model has been evaluated with no major changes in the stability (goodness of fit and model prediction) of pain intensity or psychological distress models. Investigations of the plasma proteome in patients with CWP and/or fibromyalgia have been limited. To the best of our knowledge, no studies have investigated the relationship between pain intensity and psychological distress and the plasma proteome profile.
Pain Intensity and Plasma Proteins
Pain intensity is an important facet of perception of pain in chronic pain patients. Increased pain intensity is a common feature among CWP patients (Farrar et al., 2001) and, as expected, was relatively high in CWP. The most important proteins that showed the strongest association to pain intensity were upregulated proteoforms of ceruloplasmin, fibrinogen gamma chain, alpha-1B-glycoprotein, and kininogen-1 (Table 2 and Figure 2).
Based on the interpretation of the score plot in combination with the loading plot for NRSCWP (Figures 1A,B), the proteoform of alpha-1B-glycoprotein (one of the top five proteins with a VIP > 1) was associated with lower pain intensity, whereas the other proteins were associated with higher pain intensity (Figure 1A and Table 2). Interestingly, when analyzing NRSCWP, the CWP group was divided into subgroups in the score plot according to their reported pain intensity (Figure 1B), reflecting the proteins displayed in each loading plot (Figure 1A). This subdivision within the CWP group could be the result of greater pain intensity being associated with specific metabolic and immunity proteins, which in turn reflects different ongoing protein responses. To test this hypothesis, future studies should analyze CWP patients with severe pain intensity (NRS score >7).
Fibrinogen (comprised of fibrinogen alpha, beta, and gamma chain) and kinogen-1 are known to be involved in different aspects of the blood coagulation cascade (Mosesson, 2005; Sainz et al., 2007; Wu, 2015). Kininogen-1 is primarily involved in the kallikrein-kinin system, and after cleavage one of its products triggers release of bradykinin. Bradykinin is a known mediator of pain (Wang et al., 2005), which further activates the inflammatory response through its indirect production of nitric oxide (NO) and induction of prostaglandins (Cassim et al., 2002). Kininogen-1 and bradykinin expressions were altered in the synovial fluid of rheumatoid arthritis and osteoarthritis patients (Mateos et al., 2012; Wu, 2015). Kiniogen-1 has also been found to be elevated in the plasma of farmers with musculoskeletal disorders (Ghafouri et al., 2016). In this study, both proteoforms of fibrinogen gamma chain and kininogen-1 were upregulated in CWP in the NRSCWP model, which could indicate an increase in inflammatory response.
Ceruloplasmin, an acute-phase protein, is one of the largest transport proteins for copper ions (Hellman et al., 2002). To the best of our knowledge, no direct connection between ceruloplasmin and pain intensity has been reported. Elevated levels of ceruloplasmin have been found in fibromyalgia patients compared to controls, (La Rubia et al., 2013) suggesting altered regulation of copper metabolism may be involved in the pathophysiology of FMS. In our previous plasma proteomic study, we found several proteoforms of ceruloplasmin to be altered and associated with CWP compared to CON (Wåhlén et al., 2017). One of the proteoforms of ceruloplasmin (spot number 3817), found in previous work, was also seen in this study. From the following in-depth analysis, we found that the specific ceruloplasmin proteoform was specifically associated with increased pain intensity.
By studying changes of proteins both systemically and peripherally in the trapezius muscle, the molecular signature and potential biomarkers of pain can be analyzed. For example, from the same cohort different proteoforms of alpha-1-antitrypsin have been found significantly altered in the interstitial fluid of trapezius muscle, a finding confirmed in this study (Olausson et al., 2012). One of the proteoforms of alpha-1-antitrypsin (spot number 2904) was increased and associated with pain intensity; however, the proteoforms from each study had different experimental molecular weights and pI (isoelectric point), which could be due to post-translational modifications (PTMs), although this has not been analyzed in detail and needs to be confirmed. The involvement of alpha-1-antitrypsin in fibromyalgia has been reviewed earlier (Blanco et al., 2005), suggesting that it is involved and in favor of an inflammatory response in fibromyalgia patients.
The majority of proteins with a significant association with pain intensity belonged to metabolic processes (according to the UniProt Database). Metabolic proteins have been found to be significantly altered in the trapezius muscle from females with trapezius myalgia and CWP, (Hadrevi et al., 2013; Olausson et al., 2016) suggesting a change in energy metabolism in the muscle. These metabolic proteins seem peripherally and systemically important and involved in mechanisms maintaining CWP.
In summary, pain intensity was associated with plasma proteins involved in metabolic and immunity processes. The most significant proteins were upregulated in CWP. These proteins are known acute-phase protein (ceruloplasmin), which suggests an inflammatory response (fibrinogen and kininogen-1) and changes in energy metabolism.
Psychological Distress Correlates With Immunity Proteins
The scores from both HADS-anxiety and depression were merged (HADS-total) to get an overall indication of psychological distress. There were significant higher scores in both subscales and HADS-total for CWP compared to CON (Table 1). However, at the group level, both subscales were below the cut-off values of severe symptoms (≥11).
By interpreting the score plot in combination with the loading plot for HADSCWP, three of the proteins with highest VIP value were positively associated with psychological distress: complement factor B, complement C1r subcomponent, and hemopexin. Both proteoforms of clusterin were negatively associated with HADS-total in CWP (Figures 3A,B).
Different immune cells such as microglia cells and astrocytes in the brain and macrophages in the periphery can secrete inflammatory substances that in turn can affect peripheral nociceptors in chronic pain (Ji et al., 2013, 2016). These nociceptors can generate action potentials that cause the release of specific ligands in the spinal cord that are ultimately processed by the central nervous system (CNS). They can also receive input and transmission from the CNS out to the periphery, causing local activation of immune cells (Carlton, 2014). The concept of psychoneuroimmunology (PNI) describes a multifaceted interplay between psychological, endocrine, and immune systems, (McCain et al., 2005) which has been described to be involved in fibromyalgia (Menzies et al., 2013). In this study, several of the proteins belonged to immunity process and the CWP group also had an increased psychological distress compared to CON. So far, no studies have investigated the relationship between psychological distress and plasma proteins in CWP. However, increase in pro-inflammatory cytokines and other inflammatory factors in plasma/serum from patients with depression have been reported in several studies (Dowlati et al., 2010; Dahl et al., 2014). Plasma and serum proteomic studies of patients with major depressive disorders have found altered levels of acute phase, complement, and metabolic proteins similar to our study (Lee et al., 2015; Ruland et al., 2016). These studies indicate that changed anxiety or depression status could affect proteins systemically. If this is the case in our study, this might be one explanation for the more immunity and inflammatory proteins seen in CWP. However, the expression of plasma proteins in CWP with severe psychological distress is not known (symptoms that are more related to patients with major depressive disorder), and this should be investigated in future studies.
Complement factor B and complement C1r subcomponent were both upregulated compared to CON and associated with higher HADS-total score in our study (Figures 2, 3A and Table 3). Complement factor B is essential for complement activation through the alternative pathway and activation of adaptive immune response. Complement proteins and coagulation proteins have been reported to be dysregulated in young children who later in life developed psychotic disorders (English et al., 2017).
Clusterin, also known as Apolipoprotein J, is a lipoprotein involved in several different cellular processes as lipid transportation, tissue remodeling, apoptosis and inflammation. Several proteoforms of clusterin were significantly altered and associated with higher psychological distress (Figure 3A and Table 3). Lower levels of serum clusterin has been found associated with pain in patients with hand osteoarthritis compared to healthy controls (Kropackova et al., 2018).
Hemopexin, the largest carrier protein for heme, is classified as an acute phase protein (Tolosano and Altruda, 2002). Free excessive heme (i.e., not bound to hemopexin) can result in production of free radicals and oxidative stress and potentially tissue damage, leading to activation of macrophages, release of cytokines, and induction of inflammation (Ross, 2017). Increased hemopexin levels seen in the HADSCWP model might indicate a protective effect related to a local antioxidant role (Gutteridge and Smith, 1988).
In summary, psychological distress in CWP was associated with plasma proteins related to immunity response and iron ion metabolism. Among the most significant upregulated proteins were complement factor B, complement C1r subcomponent, and hemopexin. Immunity and coagulation proteins play a part in depression; (Song et al., 1994; Lee et al., 2016), however, in this study, CWP at the group level did not exhibit severe symptoms of anxiety and depression (i.e., ≥11) (Zigmond and Snaith, 1983). However, it is plausible that an increase in psychological distress in CWP can affect and even alter immunity proteins even more, which in turn can lead to more intense and prolonged inflammatory response.
Shared Proteoforms and Post-translational Modifications
One of the advantages of using 2-DE is its ability to detect and investigate a protein’s different proteoforms and its PTMs such as truncation, phosphorylation, and glycosylation. In this study, different proteoforms of the same protein were found differentially expressed in the different MVDA models. For example, four proteoforms of clusterin were differentially expressed – one form was up-regulated and three were down regulated – in the HADSCWP model (Table 3). Differentially charged proteoforms of clusterin in plasma have been reported (Ghafouri et al., 2016). Findings like these are normally missed when using 1D or LC based proteomics. However, the physiological relevance of these different proteoforms in chronic pain have yet to be fully understood. Further studies to characterize the different proteoforms are needed before analysis with immunoassay such as western blot. By using immunoassay it is possible to detect/quantify the total amount of clusterin and to the best of our knowledge there are no commercial available antibodies against the different proteoforms of clusterin.
Glycosylated proteins may have a prolonged half-life time in circulation (Flintegaard et al., 2010). If this is the case for several of the proteins found in this study, an overall increase of these proteins might contribute to a sustained inflammatory response. Furthermore, PTMs of ion channels involved in peripheral sensitization have been well-reviewed by Bhave and Gereau (2004) and Laedermann et al. (2015) PTMs like phosphorylation of the capsaicin receptor (Transient receptor potential vanilloid 1, TRPV1) and sodium, potassium, and calcium channels expressed in primary sensory neurons can alter both the function and expression and thereby affect the transducing capability and excitability of the receptors. Although the proteins found in this study are not covered by these articles, PTMs are suggested to be involved in chronic pain. Therefore, future studies could use proteomics to detect different proteoforms with potential PTMs in different pain conditions of interest.
Shared Plasma Proteins in NRSCWP, HADSCWP, and OPLS-DA Model of CWP and CON
In total among all models presented in this study, 21 proteins were seen in our previous study comparing group differences of plasma proteins between CWP and CON using OPLS-DA analysis (Wåhlén et al., 2017). Specifically, six proteoforms (spot number 3817, 4304, 4302, 8822, 2116, and 4810) were shared among NRSCWP and two proteoforms (5819 and 4503) in HADSCWP compared to the OPLS-DA model of CWP and CON. Interestingly, in the NRSCWP model four out of these six proteoforms (spot number 3817, 4302,4304, and 8822) are the proteoforms with highest VIP value (Table 2). These proteins have been identified on both group levels with strong association to CWP and specifically related to pain intensity. In the previous study, transthyretin (spot number 2116) was more associated to CON, which is further shown in this study since it was found in BMICON (Table 4) and therefore excluded in the NRSCWP analysis. MVDA allows for the analysis of the protein patterns both on the group level, followed by in-depth analysis, and on its association to clinical parameters, which potentially could reflect the ongoing mechanisms involved in CWP.
Low-Grade Systemic Inflammation in CWP Patients
Using the same cohort, our recent analysis of the inflammatory cytokine/chemokine profile suggested a low-grade inflammation in CWP patients (Gerdle et al., 2017). The CSF proteome was analyzed in an additional cohort and showed that the proteins were involved in the immune system, apoptotic regulations, anti-inflammatory, and anti-oxidative processes, indicating presence of neuro-inflammation in the CNS of the CWP patients (Olausson et al., 2017). These results are in line with the plasma profile seen in this study and were the most discriminant proteins belonging to immunity and metabolic responses highly involved in inflammatory processes.
Strengths and Limitations
The complexity of plasma sample or other biofluids and its limitation to detect all proteins or other metabolites with one single method remains difficult. However, one advantage with using traditional 2-DE is the interpretation of a protein’s different proteoforms and potential PTMs, which has shown in this study to be of importance since a majority of the significant proteins are expressed as different proteoforms. Furthermore, 2-DE is limited in detecting large hydrophobic proteins (>200 kDa) and small peptides (<10 kDa). A gel’s gradient composition and the resolution of proteins in the first dimension could also affect the number of detected proteins in each gel. In this study, removal of albumin and IgG from plasma was used as pre-treatment of the plasma sample. It is possible that the removal procedure might have eliminated some other candidates that could be of interest. Further studies using fractionation could be used to generate a data set with more protein identifications and improved confidence. The advantage of MVDA is its application on large scale data produced when using proteomics. We have shown that MVDA is highly applicable in the proteomic field of chronic pain both when comparing proteins on a group level and when interpreting clinical parameters and its association with plasma proteins.
The interpretation of the result in this study should be taken with precaution due to its small sample size. In future studies, sample size needs to be increased. However, due to restrict inclusion/exclusion criteria we – in the context of chronic pain conditions – has achieved a relatively homogenous group of CWP patients even though some degree of heterogeneity cannot be excluded. The recruitment of the subjects in the present study took place before the current revised ACR criteria of 2016 were accepted. In future larger studies – during a transition period – it may be an advantage to describe the patients using both the ACR criteria from 1990 and the revised criteria from 2016. Moreover, future studies should include CWP patients with high and low psychological distress as well as pain free subjects with depression and/or anxiety or other psychiatric conditions can be used as positive controls. In CWP, a prominent clinical feature is fatigue and in future studies this symptom needs to be considered. In addition, it is a cross sectional study that analyses the plasma proteome at one specific time. Another aspect worth considering when validating the results is the application of additional proteomic methods such as shot gun proteomics.
This study suggests that different plasma protein patterns are associated with different pain intensities and psychological distress in CWP. Proteins belonging to the coagulation cascade and immunity processes showed strong association to each clinical outcome. Using the plasma proteome profile of CWP to study potential biomarker candidates provides a snapshot of ongoing systemic mechanisms in CWP. The effect seen systemically might be an effect of local peripheral changes in muscles and/or central changes such as central sensitization. This study suggests a numbers of potential candidates of plasma biomarkers in chronic pain that needs to be verified in different cohorts.
KW, BGh, BG, and NG designed the experiments and critically revising the paper and agree to be accountable for all aspects of the work. KW and BGh performed the experiments. KW, BGh, and BGe analyzed the data. KW and BGe wrote the original draft.
This study was supported by the Swedish Council for Working Life and Social Research (2010-0913), the Swedish Research Council (K2015-99X-21874-05-04), the Medical Research Council of Southeast Sweden (159031), AFA Insurance (Dnr-140341), Region Östergötland Research Fund (LIO-445161; SC-2013-00395-36), and the Åke Wiberg Foundation.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We would like to thank research nurse Eva-Britt Lind at the Pain and Rehabilitation Centre, Region Östergötland (Linköping) for her valuable help during the recruitment process and sample collection.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2018.02400/full#supplementary-material
Aparicio, V. A., Ortega, F. B., Carbonell-Baeza, A., Gatto-Cardia, C., Sjöström, M., Ruiz, J. R., et al. (2013). Fibromyalgia’s key symptoms in normal-weight, overweight, and obese female patients. Pain Manag. Nurs. 14, 268–276. doi: 10.1016/j.pmn.2011.06.002
Backryd, E., Lind, A. L., Thulin, M., Larsson, A., Gerdle, B., and Gordh, T. (2017a). High levels of cerebrospinal fluid chemokines point to the presence of neuroinflammation in peripheral neuropathic pain: a cross-sectional study of 2 cohorts of patients compared with healthy controls. Pain 158, 2487–2495. doi: 10.1097/j.pain.0000000000001061
Backryd, E., Tanum, L., Lind, A. L., Larsson, A., and Gordh, T. (2017b). Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J. Pain Res. 10, 515–525. doi: 10.2147/JPR.S128508
Bazzichi, L., Ciregia, F., Giusti, L., Baldini, C., Giannaccini, G., Giacomelli, C., et al. (2009). Detection of potential markers of primary fibromyalgia syndrome in human saliva. Proteomics Clin. Appl. 3, 1296–1304. doi: 10.1002/prca.200900076
Bergman, S., Herrstrom, P., Hogstrom, K., Petersson, I. F., Svensson, B., and Jacobsson, L. T. (2001). Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in a Swedish population study. J. Rheumatol. 28, 1369–1377.
Bjelland, I., Dahl, A. A., Haug, T. T., and Neckelmann, D. (2002). The validity of the hospital anxiety and depression scale. An updated literature review. J. Psychosom. Res. 52, 69–77. doi: 10.1016/S0022-3999(01)00296-3
Blanco, L. E., de Serres, F. J., Fernandez-Bustillo, E., Kassam, D. A., Arbesú, D., Rodríguez, C., et al. (2005). alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med. Hypotheses 64, 759–769. doi: 10.1016/j.mehy.2004.10.005
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., and Gallacher, D. (2006). Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain 10, 287–333. doi: 10.1016/j.ejpain.2005.06.009
Cao, Z., Tang, H. Y., Wang, H., Liu, Q., and Speicher, D. W. (2012). Systematic comparison of fractionation methods for in-depth analysis of plasma proteomes. J. Proteome Res. 11, 3090–3100. doi: 10.1021/pr201068b
Culic, O., Cordero, M. D., Zanic-Grubisic, T., Somborac-Baèura, A., Puèar, L. B., Detel, D., et al. (2016). Serum activities of adenosine deaminase, dipeptidyl peptidase IV and prolyl endopeptidase in patients with fibromyalgia: diagnostic implications. Clin. Rheumatol. 35, 2565–2571. doi: 10.1007/s10067-016-3377-8
Dahl, J., Ormstad, H., Aass, H. C., Malt, U. F., Bendz, L. T., Sandvik, L., et al. (2014). The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45, 77–86. doi: 10.1016/j.psyneuen.2014.03.019
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., et al. (2010). A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446–457. doi: 10.1016/j.biopsych.2009.09.033
English, J. A., Lopez, L. M., O’Gorman, A., Föcking, M., Hryniewiecka, M., Scaife, C., et al. (2017). Blood-based protein changes in childhood are associated with increased risk for later psychotic disorder: evidence from a nested case-control study of the ALSPAC longitudinal birth cohort. Schizophr. Bull. 44, 297–306. doi: 10.1093/schbul/sbx075
Farrar, J. T., Young, J. P. Jr., LaMoreaux, L., Werth, J. L., and Poole, R. M. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149–158. doi: 10.1016/S0304-3959(01)00349-9
Flintegaard, T. V., Thygesen, P., Rahbek-Nielsen, H., Levery, S. B., Kristensen, C., Clausen, H., et al. (2010). N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology 151, 5326–5336. doi: 10.1210/en.2010-0574
Flodin, P., Martinsen, S., Lofgren, M., Bileviciute-Ljungar, I., Kosek, E., and Fransson, P. (2014). Fibromyalgia is associated with decreased connectivity between pain- and sensorimotor brain areas. Brain Connect. 4, 587–594. doi: 10.1089/brain.2014.0274
Gerdle, B., Ghafouri, B., Ghafouri, N., Backryd, E., and Gordh, T. (2017). Signs of ongoing inflammation in female patients with chronic widespread pain: a multivariate, explorative, cross-sectional study of blood samples. Medicine 96:e6130. doi: 10.1097/MD.0000000000006130
Gerdle, B., Larsson, B., Forsberg, F., Ghafouri, N., Karlsson, L., Stensson, N., et al. (2014). Chronic widespread pain: increased glutamate and lactate concentrations in the trapezius muscle and plasma. Clin. J. Pain 30, 409–420. doi: 10.1097/AJP.0b013e31829e9d2a
Gerdle, B., Soderberg, K., Salvador Puigvert, L., Rosendal, L., and Larsson, B. (2010). Increased interstitial concentrations of pyruvate and lactate in the trapezius muscle of patients with fibromyalgia: a microdialysis study. J. Rehabil. Med. 42, 679–687. doi: 10.2340/16501977-0581
Ghafouri, B., Carlsson, A., Holmberg, S., Thelin, A., and Tagesson, C. (2016). Biomarkers of systemic inflammation in farmers with musculoskeletal disorders; a plasma proteomic study. BMC Musculoskelet. Disord. 17:206. doi: 10.1186/s12891-016-1059-y
Ghafouri, N., Ghafouri, B., Larsson, B., Stensson, N., Fowler, C. J., and Gerdle, B. (2013). Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain 154, 1649–1658. doi: 10.1016/j.pain.2013.05.002
Hadrevi, J., Bjorklund, M., Kosek, E., Hällgren, S., Antti, H., Fahlström, M., et al. (2015). Systemic differences in serum metabolome: a cross sectional comparison of women with localised and widespread pain and controls. Sci. Rep. 5:15925. doi: 10.1038/srep15925
Hadrevi, J., Ghafouri, B., Larsson, B., Gerdle, B., and Hellstrom, F. (2013). Multivariate modeling of proteins related to trapezius myalgia, a comparative study of female cleaners with or without pain. PLoS One 8:e73285. doi: 10.1371/journal.pone.0073285
Hellman, N. E., Kono, S., Mancini, G. M., Hoogeboom, A. J., De Jong, G. J., and Gitlin, J. D. (2002). Mechanisms of copper incorporation into human ceruloplasmin. J. Biol. Chem. 277, 46632–46638. doi: 10.1074/jbc.M206246200
Kliger, M., Stahl, S., Haddad, M., Suzan, E., Adler, R., and Eisenberg, E. (2015). Measuring the intensity of chronic pain: are the visual analogue scale and the verbal rating scale interchangeable? Pain Pract. 15, 538–547. doi: 10.1111/papr.12216
Kropackova, T., Sleglova, O., Ruzickova, O., Vencovsky, J., Pavelka, K., and Senolt, L. (2018). Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskelet. Disord. 19:264. doi: 10.1186/s12891-018-2179-3
La Rubia, M., Rus, A., Molina, F., and Del Moral, M. L. (2013). Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status? Clin. Exp. Rheumatol. 31(6 Suppl. 79), S121–S127.
Laedermann, C. J., Abriel, H., and Decosterd, I. (2015). Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes. Front. Pharmacol. 6:263. doi: 10.3389/fphar.2015.00263
Lee, J., Joo, E. J., Lim, H. J., Park, J. M., Lee, K. Y., Park, A., et al. (2015). Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses. Psychiatry Investig. 12, 249–259. doi: 10.4306/pi.2015.12.2.249
Lee, M. Y., Kim, E. Y., Kim, S. H., Cho, K. C., Ha, K., Kim, K. P., et al. (2016). Discovery of serum protein biomarkers in drug-free patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 69, 60–68. doi: 10.1016/j.pnpbp.2016.04.009
Lisspers, J., Nygren, A., and Soderman, E. (1997). Hospital anxiety and depression scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr. Scand. 96, 281–286. doi: 10.1111/j.1600-0447.1997.tb10164.x
Liu, X. D., Zeng, B. F., Xu, J. G., Zhu, H. B., and Xia, Q. C. (2006). Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics 6, 1019–1028. doi: 10.1002/pmic.200500247
Magdeldin, S., Enany, S., Yoshida, Y., Xu, B., Zhang, Y., Zureena, Z., et al. (2014). Basics and recent advances of two dimensional- polyacrylamide gel electrophoresis. Clin. Proteomics 11:16. doi: 10.1186/1559-0275-11-16
Malatji, B. G., Meyer, H., Mason, S., Engelke, U. F. H., Wevers, R. A., van Reenen, M., et al. (2017). A diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study of selected patients and controls. BMC Neurol. 17:88. doi: 10.1186/s12883-017-0863-9
Mansfield, K. E., Sim, J., Jordan, J. L., and Jordan, K. P. (2016). A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain 157, 55–64. doi: 10.1097/j.pain.0000000000000314
Mateos, J., Lourido, L., Fernandez-Puente, P., Calamia, V., Fernández-López, C., Oreiro, N., et al. (2012). Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J. Proteomics 75, 2869–2878. doi: 10.1016/j.jprot.2011.12.042
McCain, N. L., Gray, D. P., Walter, J. M., and Robins, J. (2005). Implementing a comprehensive approach to the study of health dynamics using the psychoneuroimmunology paradigm. ANS Adv. Nurs. Sci. 28, 320–332. doi: 10.1097/00012272-200510000-00004
Menzies, V., Lyon, D. E., Elswick, R. K. Jr., Montpetit, A. J., and McCain, N. L. (2013). Psychoneuroimmunological relationships in women with fibromyalgia. Biol. Res. Nurs. 15, 219–225. doi: 10.1177/1099800411424204
Neumann, L., Lerner, E., Glazer, Y., Bolotin, A., Shefer, A., and Buskila, D. (2008). A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin. Rheumatol. 27, 1543–1547. doi: 10.1007/s10067-008-0966-1
Olausson, P., Gerdle, B., Ghafouri, N., Larsson, B., and Ghafouri, B. (2012). Identification of proteins from interstitium of trapezius muscle in women with chronic myalgia using microdialysis in combination with proteomics. PLoS One 7:e52560. doi: 10.1371/journal.pone.0052560
Olausson, P., Gerdle, B., Ghafouri, N., Sjostrom, D., Blixt, E., and Ghafouri, B. (2015). Protein alterations in women with chronic widespread pain–An explorative proteomic study of the trapezius muscle. Sci. Rep. 5:11894. doi: 10.1038/srep11894
Olausson, P., Ghafouri, B., Backryd, E., and Gerdle, B. (2017). Clear differences in cerebrospinal fluid proteome between women with chronic widespread pain and healthy women - a multivariate explorative cross-sectional study. J. Pain Res. 10, 575–590. doi: 10.2147/JPR.S125667
Olausson, P., Ghafouri, B., Ghafouri, N., and Gerdle, B. (2016). Specific proteins of the trapezius muscle correlate with pain intensity and sensitivity - an explorative multivariate proteomic study of the trapezius muscle in women with chronic widespread pain. J. Pain Res. 9, 345–356. doi: 10.2147/JPR.S102275
Perez de Heredia-Torres, M., Huertas-Hoyas, E., Maximo-Bocanegra, N., Palacios-Cena, D., and Fernandez-De-Las-Penas, C. (2016). Cognitive performance in women with fibromyalgia: a case-control study. Aust. Occup. Ther. J. 63, 329–337. doi: 10.1111/1440-1630.12292
Ruland, T., Chan, M. K., Stocki, P., Grosse, L., Rothermundt, M., Cooper, J. D., et al. (2016). Molecular serum signature of treatment resistant depression. Psychopharmacology 233, 3051–3059. doi: 10.1007/s00213-016-4348-0
Rus, A., Molina, F., Gasso, M., Camacho, M. V., Peinado, M. A., and del Moral, M. L. (2016). Nitric oxide, inflammation, lipid profile, and cortisol in normal- and overweight women with fibromyalgia. Biol. Res. Nurs. 18, 138–146. doi: 10.1177/1099800415591035
Sainz, I. M., Pixley, R. A., and Colman, R. W. (2007). Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb. Haemost. 98, 77–83. doi: 10.1160/TH07-04-0250
Song, C., Dinan, T., and Leonard, B. E. (1994). Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 30, 283–288. doi: 10.1016/0165-0327(94)90135-X
Staud, R., Nagel, S., Robinson, M. E., and Price, D. D. (2009). Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain 145, 96–104. doi: 10.1016/j.pain.2009.05.020
Staud, R., Vierck, C. J., Cannon, R. L., Mauderli, A. P., and Price, D. D. (2001). Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91, 165–175. doi: 10.1016/S0304-3959(00)00432-2
Wåhlén, K., Olausson, P., Carlsson, A., Ghafouri, N., Gerdle, B., and Ghafouri, B. (2017). Systemic alterations in plasma proteins from women with chronic widespread pain compared to healthy controls: a proteomic study. J. Pain Res. 10, 797–809. doi: 10.2147/JPR.S128597
Wang, H., Kohno, T., Amaya, F., Brenner, G. J., Ito, N., Allchorne, A., et al. (2005). Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J. Neurosci. 25, 7986–7992. doi: 10.1523/JNEUROSCI.2393-05.2005
Wheelock, A. M., and Wheelock, C. E. (2013). Trials and tribulations of ’omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol. Biosyst. 9, 2589–2596. doi: 10.1039/c3mb70194h
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., et al. (1990). The American college of rheumatology criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990, 160–172. doi: 10.1002/art.1780330203
Xiao, Y., Haynes, W. L., Michalek, J. E., and Russell, I. J. (2013). Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol. Int. 33, 1259–1264. doi: 10.1007/s00296-012-2538-6
Zanette, S. A., Dussan-Sarria, J. A., Souza, A., Deitos, A., Torres, I. L. S., and Caumo, W. (2014). Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol. Pain 10:46. doi: 10.1186/1744-8069-10-46
Zhang, Y. G., Jiang, R. Q., Guo, T. M., Wu, S. X., and Ma, W. J. (2014). MALDI-TOF-MS serum protein profiling for developing diagnostic models and identifying serum markers for discogenic low back pain. BMC Musculoskelet. Disord. 15:193. doi: 10.1186/1471-2474-15-193
Keywords: biomarker, fibromyalgia, pain, psychological distress, inflammation
Citation: Wåhlén K, Ghafouri B, Ghafouri N and Gerdle B (2018) Plasma Protein Pattern Correlates With Pain Intensity and Psychological Distress in Women With Chronic Widespread Pain. Front. Psychol. 9:2400. doi: 10.3389/fpsyg.2018.02400
Received: 06 September 2018; Accepted: 14 November 2018;
Published: 29 November 2018.
Edited by:Changiz Mohiyeddini, Northeastern University, United States
Reviewed by:Federica Ciregia, University of Liège, Belgium
Robert David Gerwin, Johns Hopkins Medicine, United States
Copyright © 2018 Wåhlén, Ghafouri, Ghafouri and Gerdle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Karin Wåhlén, firstname.lastname@example.org